AJMC articleshttps://www.ajmc.com/newsAJMC articles© 2026 MJH Life Sciences™ and AJMC. All rights reserved.Mon, 31 Aug 2026 06:07:51 +00005en-us14447https://www.ajmc.com/newshttps://www.ajmc.com/logo.webphttps://www.ajmc.com/view/20-years-of-adc-trials-in-lymphoma-leave-many-questions-unanswered-authors-sayhttps://www.ajmc.com/view/20-years-of-adc-trials-in-lymphoma-leave-many-questions-unanswered-authors-say<![CDATA[Systematic review maps 410 lymphoma antibody drug conjugates clinical trials, revealing limited diversity beyond MMAE, few survival end points, and scarce biomarkers in DLBCL and classical Hodgkin lymphoma.]]>Sun, 30 Aug 2026 18:08:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/myasthenia-gravis-linked-to-greater-longevity-than-multiple-sclerosishttps://www.ajmc.com/view/myasthenia-gravis-linked-to-greater-longevity-than-multiple-sclerosis<![CDATA[Patients with myasthenia gravis (MG) lived 15 to 19 years longer than those with multiple sclerosis (MS) across 4 datasets.]]>Sun, 30 Aug 2026 15:28:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/what-it-will-take-to-advance-hepatitis-b-elimination-helen-nde-mphhttps://www.ajmc.com/view/what-it-will-take-to-advance-hepatitis-b-elimination-helen-nde-mph<![CDATA[Hepatitis B elimination requires expanded vaccination, screening, treatment, and education, Helen Nde, MPH, said. ]]>Sun, 30 Aug 2026 14:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/fda-approves-rusfertide-to-treat-erythrocytosis-in-polycythemia-verahttps://www.ajmc.com/view/fda-approves-rusfertide-to-treat-erythrocytosis-in-polycythemia-vera<![CDATA[FDA approves rusfertide, a first-in-class hepcidin-mimetic for polycythemia vera, cutting phlebotomies and improving hematocrit control and QOL.]]>Sat, 29 Aug 2026 15:43:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/geographic-barriers-limit-access-to-cataract-surgeryhttps://www.ajmc.com/view/geographic-barriers-limit-access-to-cataract-surgery<![CDATA[Traveling a greater distance for cataract surgery significantly lowered the odds of receiving it, with each 100 miles cutting odds by 14% overall.]]>Sat, 29 Aug 2026 14:15:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/study-measures-both-patient-and-physician-preferences-after-covalent-btk-inhibitors-in-r-r-mclhttps://www.ajmc.com/view/study-measures-both-patient-and-physician-preferences-after-covalent-btk-inhibitors-in-r-r-mcl<![CDATA[China survey reveals what R/R mantle cell lymphoma patients and doctors value after BTK failure—overall survival tops trade-offs despite CRS risk.]]>Sat, 29 Aug 2026 13:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/the-struggle-is-real-for-car-t-cell-therapy-kerry-rogers-mdhttps://www.ajmc.com/view/the-struggle-is-real-for-car-t-cell-therapy-kerry-rogers-md<![CDATA[Lymphomas arise from immune system cells and can create an environment less hospitable to CAR T-cell expansion, explained Kerry Rogers, MD.]]>Sat, 29 Aug 2026 12:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/health-equity-access-weekly-roundup-august-28-2026https://www.ajmc.com/view/health-equity-access-weekly-roundup-august-28-2026<![CDATA[Transplant weight-loss access, a new dermatomyositis drug, mifepristone safety views, and racial gaps in cataract surgery and CRC mortality.]]>Fri, 28 Aug 2026 18:55:45 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/mri-shows-hypothalamic-atrophy-in-narcolepsy-type-1-sparing-subregionhttps://www.ajmc.com/view/mri-shows-hypothalamic-atrophy-in-narcolepsy-type-1-sparing-subregion<![CDATA[This study links NT1 to anterior hypothalamus shrinkage, advancing orexin/hypocretin insights and a potential biomarker for narcolepsy with cataplexy.]]>Fri, 28 Aug 2026 18:43:31 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/doj-abandons-olmstead-defense-as-texas-v-kennedy-advanceshttps://www.ajmc.com/view/doj-abandons-olmstead-defense-as-texas-v-kennedy-advances<![CDATA[DOJ policy shifts have put HHS on the same side as states seeking to narrow Section 504's disability integration mandate in Texas v Kennedy.]]>Fri, 28 Aug 2026 18:30:27 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/inebilizumab-reduces-exacerbations-in-gmg-mint-trial-analysishttps://www.ajmc.com/view/inebilizumab-reduces-exacerbations-in-gmg-mint-trial-analysis<![CDATA[The phase 3 MINT trial found inebilizumab significantly reduced exacerbations and rescue therapy use in patients with generalized myasthenia gravis.]]>Fri, 28 Aug 2026 18:10:58 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/psoriasis-biologic-therapy-linked-to-lower-cardiovascular-riskhttps://www.ajmc.com/view/psoriasis-biologic-therapy-linked-to-lower-cardiovascular-risk<![CDATA[In this analysis, all 4 biologic classes showed reduced risk, and the CV benefit remained consistent across White, Black, and Asian patients.]]>Fri, 28 Aug 2026 17:22:01 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/ajmc-in-the-press-august-28-2026https://www.ajmc.com/view/ajmc-in-the-press-august-28-2026<![CDATA[Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.]]>Fri, 28 Aug 2026 15:20:50 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/fda-expands-tirzepatide-label-to-reduce-cardiovascular-risk-in-t2dhttps://www.ajmc.com/view/fda-expands-tirzepatide-label-to-reduce-cardiovascular-risk-in-t2d<![CDATA[Tirzepatide is now approved to lower cardiovascular death, heart attack, or stroke risk in adults with type 2 diabetes.]]>Fri, 28 Aug 2026 14:49:48 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/chicago-panel-weighs-barriers-to-transplant-weight-loss-accesshttps://www.ajmc.com/view/chicago-panel-weighs-barriers-to-transplant-weight-loss-access<![CDATA[At a Chicago roundtable, clinicians detailed fragmented obesity and diabetes care, transplant-access barriers, and insurance-driven prescribing decisions.]]>Fri, 28 Aug 2026 13:30:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/the-cost-of-waiting-an-endocrinologist-s-economic-case-for-earlier-metabolic-disease-interventionhttps://www.ajmc.com/view/the-cost-of-waiting-an-endocrinologist-s-economic-case-for-earlier-metabolic-disease-intervention<![CDATA[Almandoz challenged one of the most persistent misconceptions in metabolic disease management, that obesity treatment is primarily about weight loss, arguing instead that obesity is a systemic driver of healthcare utilization across multiple high-cost disease states including type 2 diabetes, cardiovascular disease, osteoarthritis, chronic kidney disease, and MASH, and that by the time a patient develops liver cirrhosis, heart failure, or end-stage kidney disease, the financial and human costs have already become enormous and largely preventable with earlier intervention.]]>Fri, 28 Aug 2026 12:05:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/synchronize-1-through-an-endocrinologist-s-lens-weight-loss-quality-visceral-fat-and-liver-fat-reductionhttps://www.ajmc.com/view/synchronize-1-through-an-endocrinologist-s-lens-weight-loss-quality-visceral-fat-and-liver-fat-reduction<![CDATA[Almandoz described his interpretation of the SYNCHRONIZE-1 findings, noting that while substantial and statistically significant weight reduction was observed, what captured his attention most was the nature and distribution of that weight loss, with the MRI sub-study demonstrating meaningful reductions in visceral and liver fat alongside relative preservation of lean mass, collectively pointing to a quality of weight loss that is biologically distinct from generalized weight loss.]]>Fri, 28 Aug 2026 12:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/fda-approves-brepocitinib-as-first-oral-drug-for-dermatomyositishttps://www.ajmc.com/view/fda-approves-brepocitinib-as-first-oral-drug-for-dermatomyositis<![CDATA[FDA approves brepocitinib, the first oral, targeted therapy for adult dermatomyositis, backed by phase 3 VALOR data.]]>Fri, 28 Aug 2026 00:43:47 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/unvaccinated-covid-19-infection-tied-to-higher-myocarditis-riskhttps://www.ajmc.com/view/unvaccinated-covid-19-infection-tied-to-higher-myocarditis-risk<![CDATA[A 4-million-person study finds unvaccinated COVID-19 infection raises myocarditis, pericarditis, and death risk far more than the Pfizer vaccine.]]>Thu, 27 Aug 2026 21:00:05 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/obesity-is-diagnosed-everywhere-and-owned-nowhere-atlanta-clinicians-sayhttps://www.ajmc.com/view/obesity-is-diagnosed-everywhere-and-owned-nowhere-atlanta-clinicians-say<![CDATA[Atlanta clinicians described obesity care that stalls between routine diagnosis and delayed treatment, with coverage rules driving therapy choices.]]>Thu, 27 Aug 2026 20:45:37 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/zidesamtinib-offers-new-option-for-ros1-nsclc-estelamari-rodriguez-md-mphhttps://www.ajmc.com/view/zidesamtinib-offers-new-option-for-ros1-nsclc-estelamari-rodriguez-md-mph<![CDATA[Zidesamtinib offers a new second-line option for ROS1-positive NSCLC, with durable responses and strong activity against brain metastases.]]>Thu, 27 Aug 2026 19:59:06 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/thromboembolic-risk-remains-high-across-polycythemia-vera-groupshttps://www.ajmc.com/view/thromboembolic-risk-remains-high-across-polycythemia-vera-groups<![CDATA[The findings reinforce monitoring and managing thrombotic risk across the PV population rather than focusing on traditionally defined high-risk patients.]]>Thu, 27 Aug 2026 19:30:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/back-to-school-vaccines-what-clinicians-need-to-know-in-2026https://www.ajmc.com/view/back-to-school-vaccines-what-clinicians-need-to-know-in-2026<![CDATA[Experts discussed childhood vaccine recommendations, school requirements, exemptions, misinformation, and vaccine hesitancy.]]>Thu, 27 Aug 2026 17:10:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/crc-mortality-declined-nationally-but-sharp-county-disparities-remainhttps://www.ajmc.com/view/crc-mortality-declined-nationally-but-sharp-county-disparities-remain<![CDATA[County-level CRC mortality fell substantially since 2000, but some counties still had rates more than 13 times the Healthy People 2030 target in 2019.]]>Thu, 27 Aug 2026 16:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/abortion-pill-awareness-rises-as-safety-understanding-lags-kff-poll-findshttps://www.ajmc.com/view/abortion-pill-awareness-rises-as-safety-understanding-lags-kff-poll-finds<![CDATA[A poll finds awareness of the mifepristone abortion pill is rising, but safety doubts and legal battles persist.]]>Thu, 27 Aug 2026 15:25:02 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/never-screened-cervical-cancer-rates-climb-among-us-womenhttps://www.ajmc.com/view/never-screened-cervical-cancer-rates-climb-among-us-women<![CDATA[Nearly 1 in 3 women aged 21 to 29 and 1 in 7 aged 30 to 65 had never been screened for cervical cancer by 2023.]]>Thu, 27 Aug 2026 15:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/introducing-future-proofing-pharmacy-with-mark-makhinson-pharmdhttps://www.ajmc.com/view/introducing-future-proofing-pharmacy-with-mark-makhinson-pharmd<![CDATA[Mark Makhinson, PharmD, launches Future-Proofing Pharmacy, exploring AI, access, and the health-system pharmacy enterprise of 2035.]]>Thu, 27 Aug 2026 15:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/insomnia-looks-causal-for-heart-disease-but-treatment-benefit-remains-unprovenhttps://www.ajmc.com/view/insomnia-looks-causal-for-heart-disease-but-treatment-benefit-remains-unproven<![CDATA[A narrative review finds insomnia is a consistent, dose-dependent cardiovascular risk factor, but trials have not shown that treatment lowers risk.]]>Thu, 27 Aug 2026 13:00:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/remission-vs-response-redefining-treatment-goals-in-major-depressive-disorderhttps://www.ajmc.com/view/remission-vs-response-redefining-treatment-goals-in-major-depressive-disorder<![CDATA[Major depressive disorder (MDD) is a heterogeneous disorder with many unique symptom combinations. ]]>Thu, 27 Aug 2026 12:15:00 GMTAJMCusAJMC Articleshttps://www.ajmc.com/view/empowering-community-oncology-infrastructure-investments-for-bringing-novel-rrfl-therapies-to-patientshttps://www.ajmc.com/view/empowering-community-oncology-infrastructure-investments-for-bringing-novel-rrfl-therapies-to-patients<![CDATA[Tara Graff outlined a practical framework for community oncology practices looking to establish safe and successful programs with novel regimens, emphasizing that while tafasitamab-based combinations can be adopted with relatively minimal operational changes, bispecific antibodies require more deliberate infrastructure investment, but that every community site has the capacity to build this capability with the right approach.]]>Thu, 27 Aug 2026 12:10:00 GMTAJMCusAJMC Articles